How to use PSA to screen for prostate cancer

International Journal of Clinical Practice

Volumn 57, Issue 1, 2003, Pages 40-42

  Little, Brian ^a   Young, M ^a  

^a CRAIGAVON AREA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER RISK; CANCER SCREENING; CLINICAL PRACTICE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; INTERMETHOD COMPARISON; MALE; MEDICAL SPECIALIST; NATIONAL HEALTH SERVICE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; REVIEW;

AGED; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REFERRAL AND CONSULTATION; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 0037266924     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. URL: http//:nelh.nhs.uk/psatesting
2. Whitmore WF. Localised prostate cancer: management and detection issues. Lancet 1994; 343: 1263-1267.
3. Neal DE, Leung HY, Powell PH et al. Unanswered questions in screening for prostate cancer. Eur J Cancer 2000; 26: 1316-1321.
4. Morris J, McNoe B, Adam H. Screening for prostate cancer: what do general practitioners think? NZ Med J 1997; 110: 178-182.
5. Bunting PS, Goel V, Williams I, Iscoe NA. Prostate specific antigen testing in Ontario: reasons for testing patients without diagnosed prostate cancer. Can Med J 1999; 160(1): 70-75.
6. Labrie F. Candas B. Dupont A et al. Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomised controlled trial. Prostate 1999; 38(2): 83-91.
7. Horninger W. Reissigl A. Rogatsch H et al. Prostate cancer screening in the Tyrol, Austria: experience and results. Eur J Cancer 2000; 36(10): 1322-1335.
8. McNaughton Collins M, Stafford RS, Barry MJ. Age-specific patterns of prostate-specific antigen testing among primary care physician visits. J Fam Pract 2000; 49(2): 169-172.
9. Dearnaley DP, Kirby RS, Kirk D et al. Diagnosis and management of early prostate cancer. report of a British Association of Urological Surgeons working party. Br J Urol Int 1999; 83(1): 18-33.
10. Hoedemaeker RF, van der Kwast TH, Boer R et al. Pathologic features of prostate cancer found at population-based screening with a four-year interval. J Natl Cancer Inst 2001; 93(15): 1153-1158.
11. Luboldt HJ, Bex A, Swoboda A et al. The Early Detection Project Group of the German Urological Association. Early detection of prostate cancer in Germany: a study using digital rectal examination and 4.0 ng/ml prostate-specific antigen as cut-off. Eur Urol 2001; 39(2): 131-137.
12. Gustafsson O, Mansour E, Norming U et al. Prostate-specific antigen (PSA), PSA density and age-adjusted PSA reference values in screening for prostate cancer: a study of a randomly selected population of 2400 men. Scand J Urol Nephrol 1998; 32(6): 373-377.
13. Spitz MR, Currier RD, Fueger JJ et al. Familial patterns of prostate cancer: a case-control analysis. J Urol 1991; 146(5): 1305-1307.
14. Crawford ED, Leewansangtong S, Goktas S et al. Efficiency of prostate-specific antigen and digital rectal examination in screening, using 4.0 ng/ml and age-specific reference range as a cut-off for abnormal values. Prostate 1999; 38(4): 296-302.
15. Schroder FH, Roobol-Bouts M, Vis AN et al. Prostate specific antigen-based early detection of prostate cancer- validation of screening without rectal examination. Urology 2001; 57(1): 83-90.
16. Yao SL, Lu-Yao G. Interval after prostate specific antigen testing and subsequent risk of incurable prostate cancer. J Urol 2001; 166(3): 861-865.
17. Ito K, Kubota Y, Yamamoto T et al. Long term follow-up of mass screening for prostate carcinoma in men with initial prostate specific antigen levels of 4.0 ng/ml or less. Cancer 2001; 91(4): 744-751.
18. Hugosson J, Aus G, Becker C et al. Would prostate cancer detected by screening with prostate-specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population-based studies in Sweden. Br J Urol Int 2000; 85(9): 1078-1084.
19. Candas B, Cusan L, Gomez JL et al. Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer. Prostate 2000; 45(1): 19-35.
20. Babaian RJ, Johnston DA, Naccarato W et al. The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng/ml. J Urol 2001; 165(3): 757-760.
21. Ito K, Kubota Y, Suzuki K et al. Correlation of prostate-specific antigen before prostate cancer detection and clinicopathologic features: evaluation of mass screening populations. Urology 2000; 55(5): 705-709.
22. Maattanen L, Auvinen A, Stenman et al. European randomised study of prostate cancer screening: first-year results of the Finnish trial. Br J Cancer 1999; 79(7-8): 1210-1214.
23. Kirby RS, Kirby MG, Fenely MR et al. Screening for carcinoma of the prostate: a GP based study. Br J Urol 1994; 74: 64-71.
24. Oesterling JE, Jacobsen SJ, Cooner WH. The use of age specific reference ranges for serum prostate specific antigen in men 60 years old or older. J Urol 1995; 153: 1160-1163.
25. Yan Y. Intraindividual variation of prostate specific antigen measurement and implications for early detection of prostate carcinoma. Cancer 2001; 92(4): 776-780.
26. Nijs HG, Essink-Bot ML, DeKoning HJ et al. Why do men refuse or attend population-based screening for prostate cancer? J Public Health Med 2000; 22(3): 312-316.